Immunogenicity of SARS-CoV-2 vaccines in patients with cancer

Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), and non...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakkassery, Helen, Carpenter, Esme, Patten, Piers E.M., Irshad, Sheeba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345889/
https://www.ncbi.nlm.nih.gov/pubmed/35999131
http://dx.doi.org/10.1016/j.molmed.2022.07.006
_version_ 1784761530212941824
author Kakkassery, Helen
Carpenter, Esme
Patten, Piers E.M.
Irshad, Sheeba
author_facet Kakkassery, Helen
Carpenter, Esme
Patten, Piers E.M.
Irshad, Sheeba
author_sort Kakkassery, Helen
collection PubMed
description Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), and nonreplicating viral vector vaccines such as Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca). Impaired or delayed humoral and diminished T-cell responses are evident in patients with cancer, especially in patients with haematological cancers or those under active chemotherapy. Herein we review the current data on vaccine immunogenicity in cancer patients, including recommendations for current practice and future research.
format Online
Article
Text
id pubmed-9345889
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-93458892022-08-03 Immunogenicity of SARS-CoV-2 vaccines in patients with cancer Kakkassery, Helen Carpenter, Esme Patten, Piers E.M. Irshad, Sheeba Trends Mol Med Review Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), and nonreplicating viral vector vaccines such as Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca). Impaired or delayed humoral and diminished T-cell responses are evident in patients with cancer, especially in patients with haematological cancers or those under active chemotherapy. Herein we review the current data on vaccine immunogenicity in cancer patients, including recommendations for current practice and future research. The Author(s). Published by Elsevier Ltd. 2022-12 2022-08-03 /pmc/articles/PMC9345889/ /pubmed/35999131 http://dx.doi.org/10.1016/j.molmed.2022.07.006 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Kakkassery, Helen
Carpenter, Esme
Patten, Piers E.M.
Irshad, Sheeba
Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
title Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
title_full Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
title_fullStr Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
title_full_unstemmed Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
title_short Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
title_sort immunogenicity of sars-cov-2 vaccines in patients with cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345889/
https://www.ncbi.nlm.nih.gov/pubmed/35999131
http://dx.doi.org/10.1016/j.molmed.2022.07.006
work_keys_str_mv AT kakkasseryhelen immunogenicityofsarscov2vaccinesinpatientswithcancer
AT carpenteresme immunogenicityofsarscov2vaccinesinpatientswithcancer
AT pattenpiersem immunogenicityofsarscov2vaccinesinpatientswithcancer
AT irshadsheeba immunogenicityofsarscov2vaccinesinpatientswithcancer

Ejemplares similares